Arnatar Therapeutics
Latest round
- Series A
Last raised
- Apr 2024
Total raised
- $66M
Investors
- 12
About Arnatar Therapeutics
Based in Shanghai, China, and founded in 2022, Arnatar Therapeutics operates as a biopharmaceutical developer that focuses on the development of innovative nucleic acid drugs. The founding team includes Dr. Xuehai Liang, a former Ionis technology leader, and Dr. Yanfeng Wang, a former DMPK and clinical pharmacology leader at Merck, Novartis, and Ionis. Arnatar Therapeutics is dedicated to the development of innovative drugs for the treatment of liver-targeted and extra-hepatic targeting of nucleic acids, based on antisense technology. The company has developed more than 10 antisense drugs. It has also built the siRNA technology platform and the ASO technology platform, Advanced Antisense Platform, that regulates protein expression in both directions. The drugs can be used in curing common metabolic diseases and severe rare diseases. The company generates revenue by developing antisense drugs. The company will accelerate its drug pipeline and advance clinical trials, as well as the operation of its Chinese company.
Who invested in Arnatar Therapeutics
12 investors across 2 rounds
See all investors in Arnatar Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Arnatar Therapeutics
Who invested in Arnatar Therapeutics?
Arnatar Therapeutics has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Arnatar Therapeutics raised?
Arnatar Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Arnatar Therapeutics last raise money?
Arnatar Therapeutics's most recent round on record is a Series A, in Apr 2024.
What does Arnatar Therapeutics do?
Based in Shanghai, China, and founded in 2022, Arnatar Therapeutics operates as a biopharmaceutical developer that focuses on the development of innovative nucleic acid drugs.
Where is Arnatar Therapeutics headquartered?
Arnatar Therapeutics is headquartered in Shanghai, China.
Which VCs invest in companies like Arnatar Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Arnatar Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Arnatar Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.